# EDGAR Filing Document

**Accession Number:** 0001349929
**File Stem:** 0001493152-23-008809
**Filing Date:** 2023-3
**Character Count:** 9460
**Document Hash:** 8d82211f68c3a986c337a3e0dc38d90c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-008809.hdr.sgml**: 20230324

**ACCESSION NUMBER**: 0001493152-23-008809

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230324

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230324

**DATE AS OF CHANGE**: 20230324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vyant Bio, Inc.
- **CENTRAL INDEX KEY:** 0001349929
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 043462475
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35817
- **FILM NUMBER:** 23757899

**BUSINESS ADDRESS:**
- **STREET 1:** 2370 STATE ROUTE 70 WEST
- **STREET 2:** SUITE 310
- **CITY:** CHERRY HILL,
- **STATE:** NJ
- **ZIP:** 08002
- **BUSINESS PHONE:** 201.528.9200

**MAIL ADDRESS:**
- **STREET 1:** 2370 STATE ROUTE 70 WEST
- **STREET 2:** SUITE 310
- **CITY:** CHERRY HILL,
- **STATE:** NJ
- **ZIP:** 08002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CANCER GENETICS, INC
- **DATE OF NAME CHANGE:** 20111216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CANCER GENETICS INC
- **DATE OF NAME CHANGE:** 20060117

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **March 24, 2023**

**VYANT BIO, INC.**

(Exact Name of Company as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35817** | **04-3462475** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**2 Executive Campus**

**2370 State Route 70, Suite 310**

**Cherry Hill, NJ 08002**

(Address of Principal Executive Offices) (Zip Code)

Company's telephone number, including area code **(201) 479-1357**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | VYNT | The Nasdaq Capital Market |

---

Indicate by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Introductory Note**

As previously disclosed on its Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on February 3, 2023, the Board of Directors (the "Board") of Vyant Bio, Inc. (the "Company"), after an assessment of the status of the Company's efforts to seek strategic alternatives and the Company's current cash position, approved a plan on January 31, 2023 to preserve the Company's cash to be able to continue to pursue a satisfactory strategic alternative for the purpose of maximizing the value of the Company's business while also having sufficient cash to adequately fund an orderly wind down of the Company's operations (the "Cash Preservation Plan") in the event it is unable to secure a satisfactory strategic alternative.

**Item 1.02 Termination of a Material Definitive Agreement.**

In connection with the actions described in the Introductory Note above and in Item 8.01 below, on March 24, 2023, the Company terminated that certain Equity Distribution Agreement, dated April 8, 2022, by and between the Company and Canaccord Genuity LLC, regarding the issue and sale, from time to time, of shares of the Company's common stock for an aggregate offering price of up to $20,000,000.

In connection with the actions described in the Introductory Note above and in Item 8.01 below, on March 24, 2023, the Company also terminated that certain Purchase Agreement, dated March 28, 2022, by and between the Company and Lincoln Park Capital Fund, LLC, regarding the issue and sale, from time to time, of shares of the Company's common stock for an aggregate offering price of up to $15,000,000.

**Item 8.01 Other Events.**

On March 24, 2023, the Company filed post-effective amendments to certain of its registration statements previously filed with the SEC, including post-effective amendments to each of: (i) Registration Statement Nos. 333-249513, 333-252628, 333-239497, and 333-218229 on Form S-3; (ii) Registration Statement Nos. 333-191520, 333-191521, 333-196198, 333-205903, 333-256225 and 333-214599 on Form S-8; and (ii) Registration Statement No. 333-215284 and 333-264595 on Form S-1 (such post-effective amendments, collectively the "Post-Effective Amendments" and such registration statements, collectively the "Registration Statements"). In accordance with undertakings made by the Company in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any and all securities of the Company that were registered for issuance that remain unsold at the termination of the offerings, the Company removed from registration any and all securities of the Company registered but unsold under each of the Registration Statements. As a result of this deregistration, no securities remain registered for sale pursuant to the Registration Statements.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**Forward-Looking Statements**

Any statements in this Form 8-K about future expectations, plans and prospects for the Company, including but not limited to statements about its ability to identify, assess and execute a strategic transaction or realize any value from its existing assets, its ability to preserve cash in order to adequately fund an orderly wind down of the Company's operations if no transaction is consummated, the ability of creditors, shareholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the ability of the Company to continue as a going concern, the Company's workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company's existing cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "likely," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to continue to pay its obligations in the ordinary course of business as they come due; the ability to retain key personnel, the adequacy of its capital resources in light of changing circumstances, the actions of creditors of the Company and such other important factors as are set forth in the Company's annual report on Form 10-K for the year ended December 31, 2021 and quarterly reports and other filings on file thereafter with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this Form 8-K represent the Company's views as of the date of this Form 8-K. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Form 8-K.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **VYANT BIO, INC.** | **VYANT BIO, INC.** |
| Date: | March 24, 2023 | By: | */s/ Andrew D. C. LaFrence* |
|  |  | Name: | Andrew D. C. LaFrence |
|  |  | Title: | President, Chief Executive Officer and Chief Financial Officer |

---